AbbVie made a significant $650 million upfront payment for a license agreement with RemeGen, signaling a strong focus on external innovation to bolster its pipeline.
Filing excerpt
Acquired IPR&D and milestones expense for the three months ended March 31, 2026 included an upfront charge of $650 million related to a license agreement with RemeGen Co, Ltd.
What this signalsFilings often name leadership changes, deals and spending plans.
Vendors
Vendors named
sec-10qjointVentureGet every 10-Q signal for AbbVie and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/af8b82cd-1977-4505-acaf-719a52f1ab9a returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "af8b82cd-1977-4505-acaf-719a52f1ab9a",
"signal_type": "sec-10q",
"signal_subtype": "jointVenture",
"detected_at": "2026-05-12T09:24:56.954+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"detail": "AbbVie made a significant $650 million upfront payment for a license agreement with RemeGen, signaling a strong focus on external innovation to bolster its pipeline. This large-scale collaboration requires robust systems for managing partnerships, integrating data, and tracking milestones, creating opportunities for alliance management software and collaborative R&D platforms.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "Upfront charge for license agreement with RemeGen Co, Ltd.",
"dollar_millions": 650
},
"summary": "AbbVie pays $650M upfront in a major strategic licensing deal with RemeGen",
"excerpts": "Acquired IPR&D and milestones expense for the three months ended March 31, 2026 included an upfront charge of $650 million related to a license agreement with RemeGen Co, Ltd.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/abbv-20260331.htm",
"filing_date": "2026-05-08",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "03/31",
"sales_relevance": "New entity needs",
"signal_category": "strategic",
"vendors_mentioned": [
"RemeGen Co, Ltd."
]
}
}
curl https://signals.autobound.ai/v1/signals/af8b82cd-1977-4505-acaf-719a52f1ab9a \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.